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Abstract
The ERK5 cascade is a MAPK pathway that transmits both mitogenic and stress signals, yet its mechanism of activation is not
fully understood. Using intracellular calcium modifiers, we found that ERK5 activation by EGF is inhibited both by the
depletion and elevation of intracellular calcium levels. This calcium effect was found to occur upstream of MEKK2, which is
the MAP3K of the ERK5 cascade. Co-immunoprecipitation revealed that EGF increases MEKK2 binding to the adaptor protein
Lad1, and this interaction was reduced by the intracellular calcium modifiers, indicating that a proper calcium concentration
is required for the interactions and transmission of EGF signals to ERK5. In vitro binding assays revealed that the proper
calcium concentration is required for a direct binding of MEKK2 to Lad1. The binding of these proteins is not affected by c-
Src-mediated phosphorylation on Lad1, but slightly affects the Tyr phosphorylation of MEKK2, suggesting that the
interaction with Lad1 is necessary for full Tyr phosphorylation of MEKK2. In addition, we found that changes in calcium
levels affect the EGF-induced nuclear translocation of MEKK2 and thereby its effect on the nuclear ERK5 activity. Taken
together, these findings suggest that calcium is required for EGF-induced ERK5 activation, and this effect is probably
mediated by securing proper interaction of MEKK2 with the upstream adaptor protein Lad1.
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Introduction
The extracellular signal-regulated kinase5 (ERK5) signaling
cascade is composed of MEKK2/3 at the MAP3K tier [1,2],
MEK5 at the MAPKK tier [3] and ERK5 itself as the mitogen-
activated protein kinase (MAPK) component [3,4]. This cascade
was initially thought to respond to stress stimuli only, but was later
shown to be essential also for mitogenesis [5], which could be
mediated by its role in cell cycle progression [6,7], and together
with ERK2, in oncogenic transformation [8,9]. In addition, the
ERK5 cascade plays a role in the regulation of differentiation
[10,11], migration [12,13,14], neuronal survival [15], embryonic
angiogenesis [16], serial assembly of sarcomeres [17], determina-
tion of cortical neuronal fate [18] and more [19,20].
The molecular mechanism of activation of the ERK5 cascade is
not fully elucidated yet. It seems that the cascade can be activated
by more than one mechanism dependent on the extracellular
stimulus. Thus, the protein tyrosine kinase c-Src [21], the small
GTPase Ras [22], the adaptor protein Lad1 [23] and the protein
Ser/Thr kinase WNK1 [24] were all implicated in the activation
of the cascade under various conditions. However, the conditions
under which the different components operate and the inter-
relationships between them still need clarification. Upon activation
of MEKK2/3 by any one of the mechanisms, these MAP3Ks
interact with MEK5 via specific PB1 domains [25,26]. This
interaction then allows phosphorylation of MEK5 on Thr and Ser
residues in its activation loop, which consequently induces the
activation of this MAPKK component. MEK5 is specific towards
ERK5, phosphorylating it on its activation loop Tyr and Thr
residues, activating this MAPK, and thus defines the pathway as a
distinct MAPK cascade [3]. A possible alternative route for ERK5
activation acts via Gq protein-coupled receptor signaling, in which
Gaq acts as a scaffold protein to recruit PKCj that phosphorylates
and activates MEK5 [27]. Finally, at the MAPK level, the
110 kDa ERK5 seems to serve as the only active component. Its
N-terminal part shares about 50% identity with ERK1/2, while its
unique C-terminal part, which is 400 amino acids long, has no
similarity to any known kinase [19,20].
As other MAPK cascades, the ERK5 cascade seems to function
mainly through regulation of transcription. ERK5 was shown to
directly phosphorylate, and thereby activate, members of the MEF2
group of transcription factors, including MEF2C, which conse-
quently induces the transactivation of the genes like c-Jun [28] and
MEF2 [29]. ERK5 also activates other transcription factors such as
c-Myc [30], c-Fos [22,31], Fra-1 [32], SAP1a, [22], peroxisome
proliferator-activated receptor delta (PPARd), [33], and probably
also PPARc [34] and NFkB [9]. Importantly, ERK5 was shown to
posses an intrinsic transcriptional activity, which was demonstrated
to induce the Nur77 gene transcription upon calcium signals in T
cells [35]. This activity is mediated by the non-phosphorylating C-
terminal part of the ERK5, and seems to be dependent on heavy
autophosphorylation of this region of the kinase [36].
Here we studied the role of calcium, a critical and highly
versatile second messenger [37,38] that was previously shown to
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and p38 [42] cascades. Other studies also indicated that the ERK5
cascade is influenced by elevated calcium levels upon induction of
cellular stresses like H2O2 and fluid shear stress [43,44]. However,
essentially no data exist on the role of calcium in mitogenic
stimulation of ERK5, and the mechanisms involved in this
process. We show here that ERK5 activation by EGF is dependent
on proper intracellular calcium levels. We found that this effect is
probably mediated through interaction of MEKK2 with the
adaptor protein Lad1, but not by other potential activators such as
CaMKII, c-Src, or WNK1. These results indicate that similarly to
ERK1/2, calcium can regulate the activity of ERK5 by modifying
protein interactions of components of the cascade.
Materials and Methods
Reagents and antibodies
EGF, BAPTA-AM, ionomycin, PP2, KN-62 and KN-93 were
purchased from Sigma (St. Louis, MO, USA). Anti general ERK5,
MEK5, HA, tubulin and GFP antibodies (Abs) were purchased
from Sigma Israel (Rehovot, Israel). Anti phospho-ERK5 Ab was
purchased from BioSource (Camarillo, CA, USA). Anti MEKK2,
phospho-tyrosine (pY99) and Lad1 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti phospho-CREB
Ab was purchased from Cell Signaling Technology (Danvers, MA,
USA).
Buffers
Buffer A consists of 50 mM b-glycerophosphate (pH 7.3),
1.5 mM EGTA, 1 mM EDTA, 1 mM DTT and 0.1 mM sodium
orthovanadate. Buffer H is Buffer A supplemented with 1 mM
benzamidine, 10 mg/ml aprotinin, 10 mg/ml leupeptin and, 2 mg/
ml pepstatin-A. Radioimmune precipitation assay (RIPA) buffer
consists of 137 mM NaCl, 20 mM Tris (pH 7.4), 10% glycerol,
1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 2 mM EDTA,
1 mM PMSF, 1 mM sodium orthovanadate and 20 mM leupeptin.
Kinase reaction buffer (x3) consisted of 75 mM b-glycerophos-
phate (pH 7.3), 30 mM MgCl2, 1.5 mM DTT, 0.15 mM sodium
orthovanadate, 3.75 mM EGTA, 0.3 mM ATP and 30 mM
calmidazolium.
Plasmids and constructs
rMEK5a-1 was a gift from Dr. J.D. Lee (Scripps Institute).
MEK5-GFP was created by subcloning into pEGFP-N1 between
HindIII and SacII sites. MEK5(K/A) was generated by replacing
Lys194 to Ala. HA-ERK5 was a gift from Dr. J.S. Gutkind (Oral
and Pharyngeal Cancer Branch, NIH). ERK5(1–397)-GST fusion
protein was generated by inserting into BamHI and XhoI sites in
pGEX-N1(T4). WNK1 was a gift from Dr. M.H. Cobb
(University of Texas Southwestern Medical Center). GFP-
WNK1 was created by inserting into HindIII and BamH1 sites
of the pEGFP-N1. GFP-Lad1 was prepared by inserting Lad1 into
pEGFPC1 vector. GST-Lad1 was created by inserting into EcoRI
and SalI sites of pGEX-4T. pMEF2FLuc was a gift from Dr. Ron
Prywes (Columbia University). Lad1 shRNA was prepared in
pSUPER targeting sequence TGCAGGACTTTCCCTGAGG.
Cell culture and transfection
HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (FBS). Sub-
confluent cells were subjected to serum starvation (0.1% FBS) for
18 hours prior to stimulation. For transient overexpression, HeLa
cells were transiently transfected with the different plasmids using
Polyethyleneimine (PEI) [45].
Protein extraction and immunoprecipitation
The cells were washed twice with phosphate buffered saline and
once with Buffer A, scraped into Buffer H, and disrupted by
sonication. For immunoprecipitation, the cell extracts were
incubated with the proper Abs conjugated to protein A/G beads
at 4uC for 2 h. The beads were washed once with RIPA buffer and
twice with Buffer A. The immunoprecipitated complexes were
then boiled in sample buffer and subjected to Western blot analysis
using the indicated Ab. For coimmunoprecipitation, the beads
were washed three times with buffer containing 20 mM HEPEs
(pH 7.4), 2 mM MgCl2, 2 mM EGTA, 150 mM NaCl and 0.1%
Triton X-100.
Western blot analysis and quantification
Samples were subjected to 8 or 10% SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were
blocked with 2% bovine serum albumin (BSA) in TBS-T
(200 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.05% Tween-
20), and then incubated with the appropriate Abs. Membranes
were developed with alkaline phosphatase (AP) or horseradish
peroxidase (HRP)-conjugated anti mouse or anti rabbit Abs,
followed by detection with BCIP/NBT color development
substrate (Promega, Madison, WI) or enhanced chemilumines-
cence (ECL) reagents (Amersham, Arlington Heights, IL),
respectively. The intensity of the developed bands was well within
the linear range of detection. The blots were scanned and the
density of each band was analyzed with ImageJ. Each experiment
was repeated at least three times and T-test was used to find
statistic significance.
In vitro phosphorylation assay
HeLa cells were transfected with MEK5-HA and were serum-
starved for 18 hours. After different treatments, MEK5-HA was
immunoprecipitated using anti HA Ab. MEK5 activity was
determined by phosphorylating K/A-ERK5(1–397)-GST (2 mg/
ml) in kinase reaction buffer with [c
32P]-ATP (30uC, 20 min). For
MEKK2 activity, endogenous MEKK2 was immunoprecipitated
using anti MEKK2 Ab. MEKK2 activity was determined by the
phosphorylating MEK5-K/A-GST.
Luciferase assay
HeLa cells were grown in 24-well plates and transfected with
pMEF2FLuc and pRL-TK with PEI. The cells were serum starved
for 16 hrs. Three hours after the different treatments, luciferase
activities were measured using Dual-Luciferase Reporter kit
(Promega, Madison, WI) according to the product manual.
In vitro binding assay
MEKK2 was immunoprecipitated from cell lysates and
incubated with 2 mg GST-Lad1 for overnight in a buffer
containing 50 mM b-glycerophosphate, 100 mM NaCl, 1 mM
DTT supplemented with various concentrations of calcium. Each
sample was washed four times with the buffer containing the same
level of calcium.
Immunostaining
HeLa cells were plated on glass cover slips under standard
culture conditions. After serum-starvation, the cells were treated
with different stimuli and inhibitors as indicated, and the
treatment was terminated by 3 washes with PBS. Then, the cells
were subjected to fixation (3% PFA, 20 min), permeabilization
(0.2% Triton X-100, 4 min), and sequential incubation with the
appropriate primary Abs (1:100, 45 min each) and secondary Abs
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Results
Intracellular calcium levels affect ERK5 phosphorylation
Calcium, as a major second messenger, influences the ERK1/2
cascade by inducing its activation [39] or, as we recently showed,
by modifying protein-protein interactions and subcellular locali-
zations of the ERK1/2 proteins [39,40]. Interestingly, in a screen
aimed to identify upstream regulator of the related ERK5 cascade
we found that reduction of cellular calcium concentration resulted
in a strong effect on the phosphorylation of ERK5. Therefore, we
undertook to study the mechanism by which the ERK5 cascade is
regulated by calcium, starting by characterizing the effects of
calcium modifiers on ERK5 phosphorylation. For this purpose, we
co-transfected MEK5 and ERK5 into HeLa cells, which were then
pretreated with either ionomycin, an ionophore that increases the
cytosolic calcium concentration, BAPTA-AM, an intracellular
chelator of calcium, or EGTA, an extracellular chelator of
calcium. Using anti pERK5 Ab, we found that as expected [5],
EGF treatment for 15 min significantly induced the activatory
double phosphorylation of ERK5 (Fig. 1A). Pretreatment of the
cells either with ionomycin or BAPTA-AM prior to EGF
stimulation had no effect on the basal activity of ERK5, but
resulted in a significant inhibition of exogenous ERK5 phosphor-
ylation. We then examined whether endogenous ERK5 is affected
by modulated calcium concentrations as much as the exogenous
protein. Since we found that slower migration (up-shifting) of
ERK5 in SDS-PAGE is well correlated to ERK5 activation and is
much more sensitive than that detected by anti pERK5 Ab, a
phenomenon that was also reported in other studies [21,27,28], we
decided to assess the activation of endogenous ERK5 by its gel
shifting. In similarity to the overexpressed protein, also the
activation of endogenous ERK5 by EGF was inhibited by
modulated calcium concentrations (Fig. 1B). It should be noted
that the inhibitory effect of ionomycin on ERK5 activation was
slightly more significant in the exogenous ERK5 compared to the
endogenous protein (80% vs 60%). The reason for this small
difference is not known, but could be derived from improper
localization of the overexpressed protein to organelles of the
internal calcium stores, (i.e. ER or mitochondria). Upon
ionomycin treatment, the calcium levels in these organelles are
dramatically reduced [46], the portion of improperly localized
ERK5 there is further inhibited, and this increases the inhibition
levels of this MAPK.
Characterization of the calcium effect on ERK5 and
downstream transcription
We then further characterized the calcium effects, and found
that changes in extracellular calcium levels following EGTA
treatment had no effect, nor did it enhance the effect of BAPTA-
AM when both were applied to the cells (Fig. 1B and data not
shown). These calcium effects were specific to ERK5, as ERK1/2
responded with a stronger basal activation following ionomycin
treatment, and a minor augmentation of EGF-induced activity
following BAPTA-AM treatment (data not shown). Importantly,
these effects were not confined to HeLa cells, as the response of
ERK5 to calcium in Rat1 cells was very similar (data not shown).
We then followed the effects of BAPTA-AM and ionomycin on
ERK5 over time (Fig. 1C–E) and found that while BAPTA-AM
completely inhibited ERK5 phosphorylation, ionomycin treat-
ment resulted only in partial inhibition of the signal, and these
effects were consistent throughout the treatment.
We further examined whether the effects of modulated calcium
levels were transmitted to targets of ERK5, and MEF2 was
selected for this purpose since it is a well-studied substrate of
ERK5 [47]. Thus, pMEF2FLuc, a construct containing luciferase
downstream to a promoter with MEF2 binding sites, was
introduced into HeLa cells. After stimulation with EGF alone,
we observed significant increase of luciferase activity (Fig. 1F).
When the cells were pre-treated with BAPTA-AM, the EGF-
induced increase of activity was abolished. On the other hand,
treatment with ionomycin increased the basal luciferase activity.
This may be explained by the fact that other calcium signaling
components such as calcineurin facilitate the activation of MEF2s
[48] under these conditions. However, the fold increase of
luciferase activity induced by EGF stimulation was significantly
lower than that with vehicle control. This result is consistent with
the results obtained with ERK5 phosphorylation, confirming that
calcium levels influence ERK5 activity.
Calcium does not significantly affect MEK5 activity and
interactions
The activity of a number of kinases was shown to be affected
directly upon changes in calcium levels, as was well established for
the family of Ca
++/Calmodulin-dependent kinases (CaMK). We
therefore undertook to examine the possible role of calcium as a
cofactor that directly influences MEK5 activity towards ERK5.
For this purpose, the phosphorylation of K/A-ERK5(1-397)-GST
by MEK5 was assessed in vitro with different calcium concentra-
tions in the reaction solution. We used the ATP binding site
mutant which is catalytically inactive in order to eliminate the
possible effect of feedback phosphorylation by ERK5 on its
interaction However, 1 mMo r3mM calcium in the reaction had
essentially no effect on the activity of MEK5 towards ERK5 in
vitro (Fig. 2A), indicating that the examined concentrations of
calcium do not affect MEK5 activity.
Another possible mechanism for inhibition of ERK5 phosphor-
ylation is a direct interference with MEK5-ERK5 interactions. To
address this possibility, we used again the inactive isoform of
ERK5, (K/A-ERK5(1–397)-GST). This construct was attached to
glutathione beads and used for a GST-pulldown assay. Extracts of
MEK5-HA transfected HeLa cells were then incubated with the
beads in the absence of calcium (EGTA) or in the presence of
different calcium concentrations. Following washing of the beads,
levels of specifically bound MEK5-HA were assessed by Western
blot. No effect on the interaction was detected when mM calcium
concentrations were used, although higher (mM) concentrations
slightly reduced the binding of MEK5 from both stimulated and
unstimulated cells (Fig. 2B). The binding was specific since GST
by itself failed to bind MEK5 under the same conditions (data not
shown). Since the concentrations here are much above the
physiological concentration (0.1 mM in resting cells and up to
1 mM upon stimulation), it is unlikely that calcium modulates the
activity or interactions of MEK5.
The effects of calcium on the ERK5 cascade is upstream
of MEKK2 but is not regulated by CaMKII
Next, we undertook to examine whether the inhibition of ERK5
phosphorylation by BAPTA-AM and ionomycin occurs at the
level of MEKK2. For this purpose we immunoprecipitated
endogenous MEKK2 from treated HeLa cells and examined the
activity of the precipitated proteins using in vitro phosphorylation
with bacterially expressed MEK5(K/A)-GST (or GST control,
data not shown) as a substrate. Indeed, MEKK2 from EGF-
stimulated cells phosphorylated MEK5 much stronger than the
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cells (Fig. 2C). These results are not affected by autopho-
sphorylation of the recombinant MEK5 since the K/A mutation
renders this kinase inactive. We further examined the effects of
BAPTA-AM and ionomycin by repeating the procedure with
HeLa cells pretreated with these compounds. We found that
BAPTA-AM completely inhibited MEKK2 activity towards
MEK5, whereas ionomycin caused a weaker inhibition, corre-
sponding to the endogenous inhibition of the ERK5 signal (Fig. 1).
These experiments suggest that calcium affects the ERK5 cascade
either at the MAP3K or at a further upstream level. However,
since it is unlikely that calcium remains bound to the immuno-
precipitated MEKK2, we favor the possibility that the calcium
interferes with upstream steps in the MEKK2-ERK5 activation.
CaMKII is a major effector in calcium signaling, with a broad
spectrum of substrates. It has been previously shown that
Figure 1. Intracellular calcium levels affect ERK5 activation. (A) ERK5-HA was transfected into HeLa cells. After starvation, the cells were
treated with vehicle, ionomycin (1 mM) or BAPTA-AM (15 mM) for 15 min and then with EGF (20 ng/ml) for 15 min. ERK5 phosphorylation was
detected with anti pERK5 Ab. The experiment was reproduced five times. (B) Activation of endogenous ERK5 from cells after different treatments was
detected by up-shift of ERK5 detected by anti general ERK5 Ab. The experiment was reproduced five times. (C–E) The effects of ionomycin or BAPTA-
AM were observed at different time points. Quantification of three independent experiments is presented in (E). The error bars represent standard
deviation. P values (*: P,0.05; **: P,0.01) were obtained using T-test by comparing the vehicle control group and the iononmycin- or the BAPTA-AM-
treated group. (F) HeLa cells were transfected with pMEF2FLuc and pRL-TK. Luciferase activities were measured after different treatments. The value
of Y-axis represents the luciferase activity of EGF stimulated sample divided by that without treatment within each pair. The error bars stand for
standard deviation of three experiments. P values (*: P,0.05; **: P,0.01) were obtained using T-test by comparing the vehicle control group and the
iononmycin- or the BAPTA-AM-treated group.
doi:10.1371/journal.pone.0012627.g001
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CaMKII in neurons [49], and that this dependence underlies
ERK1/2 activation following ionomycin treatment. We therefore
undertook to examine the possible role of CaMKII in EGF-
mediated ERK5 signaling. For this purpose, we pretreated HeLa
cells with KN-93, a specific CaMKII inhibitor [50], and then
stimulated with EGF (Fig. 2D). We found that although the
inhibitor efficiently reduced the EGF-induced phosphorylation of
CREB, which is one of the CaMKII substrates [51], it failed to
inhibit ERK5 phosphorylation. The lack of CaMKII effect was
confirmed by another CaMKII inhibitor, KN-62 [52], which
again had no significant effect on the EGF-induced ERK5
activation under any concentration used (Fig. 2E).
Lad1 is involved in ERK5 activation by EGF
Lad1 was identified as an adaptor protein that associates with
MEKK2, and thereby regulates the ERK5 activation by EGF
[25]. Since the effects of calcium on ERK5 activity were mediated
by processes upstream of MEKK2, we undertook to examine the
role of the Lad1 in this process. First we verified that Lad1 is
indeed involved in the EGF-ERK5 pathway by modulating the
expression of Lad1 in HeLa cells. Indeed, when GFP-Lad1 (1–
366) was overexpressed in the cells, ERK5 phosphorylation upon
EGF treatment was much higher than in control transfected cells
(4+/20.8 fold, Fig. 3A) without any significant change in the
duration of the signal. On the other hand, reduction in Lad1
Figure 2. Calcium modifiers affect either MEKK2 or its
upstream components, without involvement of CaMKII. (A)
MEK5-HA transfected HeLa cells were either stimulated with EGF or left
untreated. MEK5-HA was immunoprecipitated and its in vitro kinase
activity towards K/A ERK5 (1–397)-GST was measured in the presence of
the indicated calcium concentrations. (B) Exogenously expressed MEK5-
HA was immunoprecipitated from HeLa cells, which were either
stimulated with EGF (20 ng/ml, two upper panels) or were left without
treatment (two lower panels). The MEK5 was than subjected to in vitro
binding assay with K/A ERK5(1–397)-GST, in the presence of indicated
calcium concentrations or calcium chelator EGTA. (C) MEKK2 was
immunoprecipitated from the cells treated with vehicle, BAPTA-AM or
ionomycin in combination with or without EGF (20 ng/ml). Its activity
was measured by the incorporation of radioactive phosphate to
recombinant MEK5-GST. (D) HeLa cells were pretreated with 30 mMo f
KN-93 for 30 min and then stimulated with EGF (20 ng/ml) for 10 min.
ERK5 activation was measured by band up-shift of endogenous ERK5
detected by anti general ERK5 Ab, CREB phosphorylation was detected
by anti pCREB Ab, and anti tubulin Ab was used as a loading control. (E)
ERK5-HA transfected HeLa cells were pretreated with KN-62 in different
concentrations for 1 h. After EGF stimulation, ERK5-HA activation was
measured with anti pERK5 Ab in Western blot analysis. All the
experiments in this figure were reproduced at least three times.
doi:10.1371/journal.pone.0012627.g002
Figure 3. EGF-induced ERK5 phosphorylation is mediated by c-
Src and Lad1 but not by WNK1. (A) HeLa cells were transfected with
GFP-Lad1 or vector control followed by treatment with EGF (20 ng/ml)
for the indicated times. ERK5 phosphorylation was determined using
upshift of ERK5 in blot. (B) Lad1 shRNA (Sh1–2 mg or Sh2–6 mg) or
empty vector (con) were transfected into HeLa cells. The cells were
stimulated by EGF and ERK5 phosphorylation was determined by
Western blot as in (A). The levels of endogenous Lad1 and MEKK2 were
determined by their corresponding Abs as indicated. (C) HeLa cells
were transfected with GFP-Lad1 and the activation of ERK5 in response
to EGF in the presence of ionomycin or BAPTA-AM was detected by
band shift. All the experiments in this figure were reproduced at least
three times.
doi:10.1371/journal.pone.0012627.g003
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ERK5 phosphorylation upon EGF treatment (Fig. 3B). We did not
observe the reported participation of WNK1 in EGF-induced
stimulation of ERK5 in HeLa cells [24], as in our system
overexpression of WNK1 actually reduced the EGF-stimulated
ERK5 gel retardation (data not shown). Together, these data
indicate that Lad1, but not WNK1, is likely to be involved in EGF-
induced ERK5 activation in our system.
We then examined whether Lad1 may influence the effects of
modified calcium levels on EGF-induced ERK5 activation. For
this purpose, GFP-Lad1 was overexpressed in HeLa cells, which
were later serum-starved and stimulated with EGF in the presence
or absence of BAPTA-AM and ionomycin. Similar to non-
transfected cells (Fig. 1), pretreatment of the Lad1-overexpressing
cells with ionomycin inhibited this activation for about 60%
(Fig. 3C upper panels) and BAPTA-AM abolished the EGF-
stimulated ERK5 in these cells (Fig. 3C lower panels). Therefore,
Lad1 does not protect or modify the ERK5 cascade from the
effects of changing calcium concentrations, indicating that these
effects are not likely to occur upstream of this component. Since
we ruled out an influence of calcium downstream of Lad1-
MEKK2, the interaction of Lad1 with MEKK2 might be the
responsive step to changes in calcium concentrations.
EGF induces a calcium-dependent MEKK2-Lad1
interaction
In order to study the possible effects of calcium on the
interaction of Lad1 with MEKK2, we determined their degree of
association using coimmunoprecipiatation. For this purpose GFP-
Lad1 was transfected into HeLa cells, and an anti GFP Ab was
used to co-immunoprecipitate endogenous MEKK2 with the
exogenously expressed GFP-Lad1. We found, as expected [23],
that MEKK2 and Lad1 interact with each other in resting cells
(Fig. 4A). It has been previously suggested that treatment with
EGF may disturb the interaction between the two proteins [23].
However, EGF treatment of the Lad1-transfected cells increased
the MEKK2-Lad1 interaction that peaked 5 min after stimulation
and was reduced to below basal levels 25 min later. As the
previous report showed that the reduced interaction occurs at
longer time after stimulation, we concluded that EGF initially
induces an increased interaction between the two proteins, and
this is reduced to below basal levels only at later time points.
Therefore, elevated interaction between MEKK2 and Lad1 is
probably required for the transmission of EGF signals towards
ERK5.
We then undertook to study the influence of modulated calcium
concentrations on the MEKK2-Lad1 interaction. As described
above, we pretreated the GFP-Lad1 transfected cells with BAPTA-
AM and ionomycin and then studied the degree of interaction
upon EGF stimulation. We found that ionomycin partially
reduced the EGF-stimulated MEKK2-Lad1 interaction and its
effect was maximal (70%+/212%) 15 min after stimulation. On
the other hand, BAPTA-AM abolished the interaction between
the two proteins almost completely. These results are in a good
correlation with the effect of calcium modulation on MEKK2-
ERK5 phosphorylation (Figs. 1–2), indicating that this effect on
ERK5 may be derived from the effects of calcium on MEKK2-
Lad1 interaction, which thus becomes a central regulatory process
in regulating the ERK5 cascade.
In order to determine whether the calcium effect on MEKK2-
Lad1 interaction is direct or mediated by other interacting proteins,
we further examined the interaction by an in vitro binding assay.
Thus, MEKK2 from HeLa cells treated with or without EGF was
immunoprecipitated. After thorough wash, the precipitant was
incubated with recombinant GST-Lad1 in the presence of various
levels of calcium, and this was followed by three washes with buffers
containing the same examinedcalcium concentrations. Overall, the
interaction of Lad1 with MEKK2 was stronger when MEKK2 was
immunoprecipitated from EGF-stimulated cells (Fig. 4B). More
importantly, addition of calcium indeed modified the MEKK2-
Lad1 interaction in both non-treated and EGF-stimulated samples
in a biphasic manner. Thus, the binding between the two molecules
was weak without calcium or at low calcium concentration. The
interaction was elevated in calcium concentrations of 0.5–1 mM,
which falls within the upper part of stimulated physiological levels.
Above 1 mM, the binding was reduced to a comparable level to that
of no calcium. Therefore, ourresultsconfirm thata narrowrangeof
calcium concentrations is required for strong Lad1/MEKK2
interaction.
Figure 4. MEKK2-Lad1 interaction is modulated by calcium. (A)
Exogenously expressed GFP-Lad1 was immunoprecipitated from HeLa
cells with indicated treatments. The MEKK2 molecules associated with
GFP-Lad1 was detected by anti MEKK2 Ab. The lower panel shows the
average quantification of three independent experiments. The error
bars represent standard deviation. P values (*: P,0.05; **: P,0.01) were
obtained using T-test by comparing the vehicle control group and the
iononmycin- or the BAPTA-AM-treated group. (B) MEKK2 was immu-
noprecipitated from HeLa cells without or with treatment of EGF. It was
then incubated with recombinant GST-Lad1 in the presence of various
concentrations of calcium. The associated GST-Lad1 was detected by
anti Lad1 Ab. The lower panel shows the average quantification of three
independent experiments. The error bars represent standard deviation.
P values (*: P,0.05) were obtained using T-test within each group, EGF-
treated or nontreated, by comparing the interaction at 0.25 mM calcium
and that without calcium.
doi:10.1371/journal.pone.0012627.g004
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It was previously demonstrated that both Lad1 [53] and
MEKK2 [23] are phosphorylated on tyrosine residues upon
stimulation. These phosphorylations are likely to be mediated
directly by Src family kinases, and were shown to be important for
their signaling initiated by these proteins. We therefore assessed
the possibility that calcium affects Lad1-MEKK2 interactions by
interfering with these phosphorylation events. To study the effect
of calcium on the EGF-induced Tyr phosphorylation of Lad1,
GFP-Lad1 transfected HeLa cells were pretreated with ionomycin
or BAPTA-AM prior to EGF stimulation, and GFP-Lad1 was
immunoprecipitated and subjected to Western blot analysis with
anti pTyr Ab. As expected GFP-Lad1 was Tyr phosphorylated
upon EGF treatment (Fig. 5A), and this phosphorylation was
slightly reduced by BAPTA-AM and ionomycin in all four repeats
of this experiment. However, this reduction was not statistically
significant and did not correlate with the extent by which
MEKK2-Lad1 interaction was compromised. Therefore, we
concluded that these small changes in phosphorylation do not
lead to the changes in interaction. On the other hand, the slight
reduction in Tyr phosphorylation might be the consequence of this
lack of association that is normally required for a proper
phosphorylation downstream of c-Src (Fig. 5B), which we found
to be a mediator of the EGF-induced ERK5 activation in our
system (data not shown).
We next examined the Tyr phosphorylation of MEKK2 by
immunoprecipitating the endogenous protein from treated HeLa
cells that were transfected with either GFP-Lad1 or GFP alone. As
expected, EGF stimulation of the control GFP-transfected HeLa
cells induced a strong Tyr phosphorylation of the endogenous
MEKK2, and this was inhibited by the c-Src inhibitor PP2
(Fig. 5C). Unlike the effect of overexpressed Lad1 on ERK5
phosphorylation, excess of GFP-Lad1 did not significantly change
this effect, indicating that the Tyr phosphorylation of MEKK2 is
not directly involved in ERK5 activation. Interestingly, modifica-
tion of calcium concentration slightly reduced the MEKK2 Tyr
phosphorylation (Fig. 5D), suggesting that this phosphorylation
may be dependent in part on the calcium-dependent association of
MEKK2 with Lad1.
Changes in calcium concentrations inhibit the nuclear
translocation of MEKK2
We have previously shown that ERK5 and MEK5 are localized
to the nuclei of resting, as well as EGF-stimulated cells, whereas
MEKK2 is distributed all over resting cells and accumulates in the
nucleus upon EGF stimulation [54]. Lad1 on the other hand is
localized mainly in the cytoplasm where it likely to interact with a
variety of proteins and may redistribute to the plasma membrane
upon stimulation [53]. To examine the effects of changes in
calcium concentrations on the subcellular distribution of Lad1 and
MEKK2 we immunostained HeLa cells with the proper Abs. We
found that MEKK2 was indeed localized all over the cell before
stimulation and accumulated in the nucleus upon EGF treatment
(Fig. 6). Lad1 on the other hand was mainly localized in the
cytoplasm, and its distribution was not significantly changed upon
the treatment. Treatment of the HeLa cells with ionomycin or
with BAPTA-AM did not significantly modify these localizations,
and did not modify the cytoplasmic distribution of Lad1 upon
EGF stimulation. Calcium modifiers prevented the nuclear
translocation of MEKK2 upon EGF stimulation, indicating that
calcium is involved in this mechanism. Thus, although the
modified calcium concentrations release more MEKK2 molecules
by preventing their interaction with the cytoplasmic Lad1, the free
molecules do not shuttle to the nucleus, possibly because of the
calcium effects on nuclear pore proteins [55]. ERK5 and MEK5
did not exhibit any change in their nuclear localization in these
cells. Therefore, changes in calcium concentration influence
ERK5 activity not only by modulation of MEKK2-Lad1
interaction but also by their effects on the subcellular localization
of these components, possibly by inducing interactions with
another set of anchoring proteins.
Discussion
The ERK5 cascade is a MAPK pathway that plays a role in the
regulation of various cellular processes. However, the mechanism
of activation and regulation of the ERK5 cascade are not well
understood. One signaling mechanism that was shown to regulate
the MAPK cascades is the elevation of calcium levels upon
stimulation [37,38]. Indeed, we have recently found that the
interaction of ERK1/2 with many proteins is regulated by calcium
and dysregulation of these interactions by modulating calcium
concentration leads to changes in their subcellular localization
Figure 5. Calcium modulates Tyr phosphorylation of MEKK2
but not of Lad1. HeLa cells transfected with GFP-Lad1 were subject to
different treatments as indicated (EGF 20 ng/ml; ionomycin (1 mM) or
BAPTA-AM (15 mM) for 15 min; PP2 3 mM). GFP-Lad1 was immunopre-
cipitated with anti GFP Ab (A, B). Endogenous MEKK2 was immuno-
precipitated by anti-MEKK2 Ab (C, D). Their phsophorylation on Tyr
residues was detected by pY99 Ab. The experiments in this figure were
reproduced 3 times.
doi:10.1371/journal.pone.0012627.g005
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and p38 activation [42,57]. Interestingly, in a screen aimed to
identify upstream regulators of ERK5 upon EGF stimulation, we
found that the most pronounced effects on ERK5 activation were
achieved by inducible changes in intracellular levels of calcium.
Intriguingly, we found that both increase and depletion of
intracellular calcium resulted in a significant inhibition of EGF-
induced ERK5 phosphorylation in EGF stimulated cells.
In order to identify the tier(s) in the ERK5 cascade that is
directly responsive to the changes in calcium concentration we
examined the effects of calcium modifiers on each of the cascade
components. Our results clearly show that ERK5 phosphorylation
by MEK5 is not affected by the calcium changes in vitro (Fig. 2).
On the other hand, calcium did affect the activity of immunopre-
cipitated MEKK2, which may suggest that the effect is derived
either from a direct influence on MEKK2 activity or from effects
at upstream levels. Since it is unlikely that calcium still remains
bound to the immunoprecipitated protein, we assumed that the
more likely calcium target would be an upstream component. In
order to identify this calcium targets, we then undertook to identify
the cascade that leads to MEKK2 activation upon EGF treatment
in HeLa cells. Using specific inhibitors, shRNA construct, and
protein overexpression, we found that c-Src and Lad1, but not
CaMKII or WNK1, participate in the process of activation of the
ERK5 activation. We also confirmed previous reports [23,53] that
Lad1 and MEKK2 are Tyr-phosphorylated upon EGF stimula-
tion downstream of the active c-Src (Fig. 5). Therefore, in our
system, the pathway leading from the activated EGFR to MEKK2
activation is likely to include activation of c-Src, which then
phosphorylates Lad1, which in turn associates with MEKK2. The
association of Lad1 with MEKK2 allows the activation of
MEKK2 through a process that may require Tyr phosphorylation
of the latter, and this activation is further transmitted through the
rest of the ERK5 cascade.
After elucidating the signaling components upstream the ERK5
cascade, we examined which one of them may be responsible for
mediating the reduced ERK5 phosphorylation upon changes in
calcium concentrations. Our results show that a strong effect of
varied calcium concentration was seen in MEKK2-Lad1 interac-
tion (Fig. 4), suggesting that this is the main process affected by the
modulation of calcium concentration. On the other hand, the c-
Src-mediated tyrosine phosphorylation of Lad1 was not signifi-
cantly affected (Fig. 5), indicating that neither the activation nor
activity of c-Src is significantly modified. The fact that the Tyr
phosphorylation of MEKK2 was somewhat reduced by the
calcium changes under the same conditions (Fig. 5D), may
indicate that MEKK2-Lad1 interaction plays a role in allowing
proper c-Src phosphorylation of MEKK2. Alternatively, it is also
possible that another calcium sensitive protein kinase is mediating
the c-Src-mediated MEKK2 phosphorylation. However, such an
alternative would be less likely, since a Tyr-kinase cascade
downstream of c-Src has not been demonstrated in any system.
The reduced MEKK2-Lad1 interaction upon pretreatment
with BAPTA-AM and ionomycin (Fig. 4A) indicates that restricted
and specific calcium concentrations are responsible for the
interaction. This raises the question as to how this calcium effect
is regulated. We found that an optimal calcium concentration is
required for the MEKK2-Lad1 interaction in an in vitro assay as
well (Fig. 4B), indicating that calcium influences the MEKK2-
Lad1 directly, and not via any scaffold protein. We have
previously shown that calcium may regulate the protein-protein
interaction of ERK1/2 [40,56], which may be mediated through
the cytosolic retention sequence (CRS)/common docking motif
(CD) of these ERKs. The fact that this motif contains three acidic
Figure 6. Changes in calcium concentrations do not affect Lad1 localization but inhibit nuclear MEKK2 accumulation. Serum starved
HeLa cells were pretreated with vehicle, ionomycin (1 mM) or BAPTA-AM (15 mM) for 15 min and then stimulated with EGF (20 ng/ml) for 10 min. The
cells were stained with anti Lad1 or anti MEKK2 Abs and visualized with fluorescent microscopy. This experiment was reproduced 3 times.
doi:10.1371/journal.pone.0012627.g006
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chelating the calcium, which then add positive charges to the
domain to strengthen its binding affinity. It is possible that a
sequence in MEKK2 or Lad1 functions similarly, and allows their
proper interaction. Indeed, MEKK2 contains several acidic and
hydrophobic amino acids in residues 241–260 that were shown to
be important for the MEKK2-Lad1 interaction [23], and these
residues may function similarly to the CRS/CD domain of
ERK1/2. Similar calcium effects could influence the MEKK2-
MEK5 binding via the PB1 domain in the N terminus of MEKK2
[26], but, as explained above, it is unlikely that the effects of
calcium on ERK5 activity are mediated through that level. In
addition, it should be noted that the possible calcium chelation by
acidic amino acid residues might explain the decreased interaction
upon reduced but not elevated calcium concentrations. This is
mainly because the limited number of acidic amino acids should
restrict the number of bound calcium ions per molecule. It is
possible that this higher calcium concentration causes non-specific
binding of calcium, and therefore alters the net charge of the
MEKK2-Lad1 proteins, but this should be further studied.
Another parameter examined here was the effect of calcium on
the subcellular localization of the components of the ERK5
cascade. In a previous paper [54], we found that most ERK5 and
MEK5 molecules are localized in the nucleus of Rat1 and HeLa
cells. We also showed that the nuclear MEK5 is activated by
MEKK2, which translocates into the nucleus upon EGF
stimulation. Interestingly, other reports claimed that although
ERK5 is localized in the nucleus of some cell types, it is found
primarily in the cytoplasm of others [58,59]. In the cells where the
ERK5 is localized mainly in the nucleus, it is activated due to
nuclear translocation of MEKK2 [54]. However, the small
amount of ERK5 molecules, which are retained in the cytoplasm
of these cells, are activated in the cytoplasm and then translocate
to the nucleus to increase the amount of active ERK5 at this
location [59].
We found that both BAPTA-AM and ionomycin inhibited the
nuclear translocation of MEKK2 upon EGF stimulation. These
results were somewhat surprising since we expected that the
prevention of interaction with the cytoplasmic Lad1 would release
MEKK2 for a faster nuclear translocation. The fact that the
translocation was inhibited might indicate either that the
MEKK2-Lad1 interaction is important for the nuclear transloca-
tion of MEKK2, or that calcium plays a role in the nuclear
penetration of this molecule. Since we found that calcium
regulates ERK1/2 translocation [56], the second possibility is
more likely to occur, indicating that proper calcium concentrations
are required, not only for ERK1/2, but also for MEKK2
translocation. In addition, due to the lack of correlation between
Lad1 and MEKK2 phosphorylation, as well as the inhibited
translocation of MEKK2 that do not correlate with the reduced
binding to Lad1, it can be argued that MEKK2 might be
phosphorylated and translocated to the nucleus independently of
Lad1. However, our results indicate that most MEKK2 molecules
do bind to Lad1 shortly after stimulation and therefore, we believe
that Lad1 is essential for MEKK2 activation, which is dependent
on optimal calcium concentrations. Our results also show that
calcium influences the ERK5 cascade by modulating the nuclear
translocation of MEKK2 as well.
In summary, this work presents novel regulatory aspects of
EGF-induced ERK5 activation, mainly in regard to the role of
intracellular calcium, as well as the process of nuclear translocation
that accompanies this activation. We found that ERK5 activation
by EGF is inhibited by both reduction and elevation of
intracellular calcium levels. The changes in calcium were found
to influence mainly the MEKK2-Lad1 interaction, and in vitro
binding assays revealed that the proper calcium concentration is
required for a direct MEKK2-Lad1 binding. The binding of these
proteins is not affected by c-Src mediated phosphorylation on
Lad1, but by itself slightly affects the Tyr phosphorylation of
MEKK2, indicating a requirement for proper interaction to
induce Tyr phosphorylation of MEKK2. In addition, we found
that MEKK2 is distributed all over resting cells, and Lad1 appears
mainly in the cytoplasm. Upon EGF stimulation MEKK2
accumulates in the nucleus where it can phosphorylate MEK5,
while the localization of Lad1 remains unaffected. As changes in
calcium levels inhibit EGF-induced MEKK2 translocation and
nuclear accumulation, it is likely that this effect is due to a direct
influence on its mechanism of translocation, independent of Lad1.
Taken together, these findings suggest that calcium is required for
EGF-induced ERK5 activation by securing the proper interaction
of the MEKK2 at the MAP3K level of this cascade with the
upstream adaptor protein Lad1.
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